Oct 2026· Frontiers in Neuroscience· Vol 20, pp.
1901494
· 0 citations· 203 references
Medicine
TL;DR
Three-dimensional culture systems, including tumor spheroids and organoids, are emphasized, which more effectively recapitulate tumor architecture, cell-cell interactions, and drug penetration gradients than conventional two-dimensional models.
Abstract
IDH-wildtype glioblastoma, or glioblastoma multiforme (GBM), is the most aggressive primary malignancy of the central nervous system. It is characterized by marked invasiveness, intratumoral heterogeneity, and high recurrence rates, largely driven by intrinsic and acquired resistance to standard temozolomide (TMZ) therapy. TMZ is an oral alkylating agent that methylates nitrogenous bases, mainly forming O6-methylguanine (O6-meG) lesions, the main cytotoxic and mutagenic events responsible for its antitumor effects. This review first characterizes gliomas and the mechanism of action of the main GBM treatment drug (TMZ), then critically examines in vitro cell culture models investigating these mechanisms. This review emphasizes the development and application of three-dimensional (3D) culture systems, including tumor spheroids and organoids, which more effectively recapitulate tumor architecture, cell-cell interactions, and drug penetration gradients than conventional two-dimensional models. This review discusses the strengths and limitations of these models and their translational relevance to modeling TMZ sensitivity and resistance in GBM.
Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant brain tumors, highlighting the urgent need for experimental models that can faithfully recapitulate its complex biology. In vitro models are essential tools for investigating GBM biology and for preclinical drug development. Conventional two-...
Claudia Orlanno, E. Lamparelli, Adamo Lancellotti et al.· Biofabrication· 0 citations
Glioblastomas (GBMs) are highly invasive and heterogeneous in nature which strongly contributes to poor survival of patients, averaging 15 months after diagnosis. With little treatment options being available in particular for addressing GBM invasiveness, there is a high need for supplementary therapies in addition to...
Kim K. Wagner, A. J. Yool, Rohan A. Davis et al.· Cancer Cell International· 0 citations
Introduction Glioblastoma remains one of the most treatment-resistant cancers, and temozolomide (TMZ) resistance is a central barrier to durable clinical response. Inhibition of exportin-1 (XPO1) by selinexor has emerged as a promising strategy to overcome resistance in solid tumors; however, its ability to sensitize T...
Beyza Ozturk, A. Çelebi, D. Kılıç et al.· Frontiers in Oncology· 0 citations
Background Temozolomide (TMZ) remains the first-line chemotherapeutic agent for glioblastoma (GBM), but its clinical efficacy is often limited by acquired resistance. This study aimed to investigate whether nectin-4 could serve as a target to sensitize GBM cells to TMZ and to determine whether resveratrol enhances TMZ...
Glioblastoma multiforme (GBM) is an astrocytoma classified among the most aggressive brain tumors. Currently considered incurable, patients have a median survival of 15 months after diagnosis. Treatment typically involves tumor resection followed by radiotherapy and chemotherapy. Temozolomide is the most commonly used...
Ayşe Mine Yılmaz, Burak Kızılca, Zafer Alparslan et al.· Journal of Research in Pharm...· 0 citations
Targeting the mTORC2/AKT/BABAM1 axis with vistusertib worked synergistically with TMZ in GBM by impairing the BRCA1-A complex and HR repair and sustained tumour suppression in both 2D and 3D models.
Napatsakon Youngsanbhu· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.